Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Exenatide (Byetta / Bydureon)
An educational, source-based comparison of Cagrilintide and Exenatide (Byetta / Bydureon) — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
First-in-class GLP-1 receptor agonist for type 2 diabetes.
Synthetic version of exendin-4 (originally from Gila monster saliva). Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety.
- Type 2 diabetes
- Weight management (off-label)
- • FDA-approved.
- • Nausea common; pancreatitis warning.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cagrilintide | Cagrilintide plus semaglutide for obesity (Phase 2) | The Lancet | 2021 | Combination produced greater weight loss than either agent alone. |
| Exenatide (Byetta / Bydureon) | EXSCEL trial | NEJM | 2017 | Cardiovascular safety established for once-weekly exenatide. |
Side-effect & safety grid
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.
- FDA-approved.
- Nausea common; pancreatitis warning.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cagrilintide vs Exenatide (Byetta / Bydureon) — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Exenatide (Byetta / Bydureon) is GLP-1 Agonist · Metabolic.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Exenatide (Byetta / Bydureon) — type 2 diabetes.
- Tag: Weight loss vs FDA-Approved · Metabolic.